CCRM's OmniaBio Partners with Avectas to Advance Automated Cell Therapy Manufacturing
- OmniaBio, Canada's largest cell and gene therapy CDMO, will evaluate Avectas' automated manufacturing platform to enhance scalability and efficiency.
- CCRM is expanding its global hub-and-spoke network across Canada, Australia, Nordic countries, and a planned Ireland facility to support regional advanced therapy manufacturing.
- The partnership targets automation, cost reduction, and standardization challenges that currently limit patient access to cell and gene therapies.
Operational Impact
OmniaBio's evaluation of Avectas' platform could enhance its Intelligent Factory capabilities and support CCRM's planned Ireland hub, potentially increasing regional manufacturing capacity and reducing time-to-patient for cell therapies across EMEA and APAC.
Source: PR Newswire pharma category RSS
References
- PR Newswire pharma category RSS — CCRM's OmniaBio Partners with [Avectas to Advance Automated Cell Therapy Manufacturing](https://www.prnewswire.com/news-releases/ccrm-omniabio-and-avectas-partner-to-improve-cell-therapy-manufacturing-302799943.html)